News & Views
Evox Therapeutics Completes Acquisition of Exosome AAV Technology and Intellectual Property
Jul 04 2023
Oxford-based biotech Evox therapeutics, a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, has purchased Codiak Biosciences’ engEx-AAV™ technology platform. The agreement includes all intellectual property rights, as well as securing exclusive access to certain engineering and manufacturing rights associated with it. This technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models and to shield AAVs from neutralising antibodies.
Focused on developing an entirely new class of therapeutics for the treatment of severe rare diseases, Evox uses its proprietary DeliverEX® technology to engineer exosomes to facilitate drug delivery to organs of interest, including the brain and the central nervous system. This approach has potential to address some of the limitations of genetic medicines such as gene therapy, gene editing and RNA therapeutics by enabling safe non-immunogenic repeated delivery to cells and tissues that are currently out of reach using other drug delivery technologies. It is backed by leading life sciences venture capital groups including Redmile and OrbiMed, and is supported by a comprehensive intellectual property portfolio.
“We are pleased to now own this technology and look forward to applying it in future exosome AAV programs. This acquisition further adds to our dominant intellectual property portfolio of patents that cover key aspects needed to develop and commercialise exosome therapeutics including their design, composition, and manufacture,” said Per Lundin, PhD, Chief Business Officer & Co-Founder of Evox Therapeutics. “This is part of our long-term business strategy of leveraging improved exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors.”
More information online
Buyers Guide - Major producers of analytical equipment who wish to introduce and sell their products to buyers in science and industry - Over 1,000 products and services that these companys man...
View all digital editions
Jan 17 2024 Birmingham, UK
Jan 24 2024 Tokyo, Japan
Jan 29 2024 Dubai, UAE
Jan 31 2024 Tokyo, Japan
Feb 03 2024 Boston, MA, USA